| Literature DB >> 34976892 |
Luiza M Neves1, Lorena M Haefeli1, Andrea A Zin1, Ricardo E Steffen2,3, Zilton F M Vasconcelos1, Márcia Pinto1.
Abstract
Purpose: To evaluate the cost-utility of wide-field imaging (WFI) as a complementary technology for retinopathy of prematurity (ROP) screening from the Brazilian Unified Health System's perspective. Introduction: ROP is one of the leading causes of avoidable childhood blindness worldwide, especially in middle-income countries. The current ROP screening involves indirect binocular ophthalmoscopy (IBO) by ROP expert ophthalmologists. However, there is still insufficient ROP screening coverage. An alternative screening strategy is the combination of WFI with IBO.Entities:
Keywords: Brazil; costs and cost analysis; diagnosis; healthcare economics; neonatal screening; quality-adjusted life years (QALY); retinopathy of prematurity; telemedicine
Year: 2021 PMID: 34976892 PMCID: PMC8716796 DOI: 10.3389/fped.2021.757258
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Decision analytic model for ROP care in preterm and/or low birth weight infants with two strategies: the current stratagy, indirect binocular ophthalmoscopy, and the comparing strategy, combination of wide-field imaging with indirect binocular ophthalmoscopy. The number under the branches of the decision tree represents the probability of each parameter branch to happen.
Parameter estimates used in the model divided by screening, treatment, and follow-up categories.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| Access to ophthalmoscopy | 0.52 | 0.20–0.80 | ( | Lognormal |
| Access to combination | 0.90 | 0.52–0.95 | Assumption | Lognormal |
| Ophthalmoscopy sensitivity | 0.867 | 0.70–0.90 | ( | Lognormal |
| Ophthalmoscopy specificity | 0.962 | 0.70–0.97 | ( | Lognormal |
| Wide-field imaging sensitivity | 0.933 | 0.455–0.952 | ( | Lognormal |
| Wide-field imaging specificity | 0.962 | 0.617–0.98 | ( | Lognormal |
| Good-quality imaging | 0.95 | 0.90–0.98 | ( | Lognormal |
| ROP type 2 or worse | 0.208 | 0.05–0.25 | ( | Lognormal |
| No. of examinations in infants not requiring laser treatment | ( | 1–13 | Unit observation from 2006 to 2019 | Lognormal |
| No. of examinations in infants requiring laser treatment | ( | 2–15 | Unit observation from 2006 to 2019 | Lognormal |
|
| ||||
| ROP needing treatment | 0.08 | 0.07–0.10 | ( | Lognormal |
| Two treatments needed | 0,12 | 0.11–0.20 | Unit observation from 2006 to 2019, ( | Lognormal |
| Facectomy (cataract surgery) | 0.0109 | 0.005–0.05 | ( | Lognormal |
| Good visual function after treatment | 0.753 | 0.60–0.857 | ( | Lognormal |
| Poor visual function when treatment is indicated and not performed | 0.643 | 0.50–0.80 | ( | Lognormal |
|
| ||||
| Good visual function | 0.701/13.65 | 7.0–66.6 | ( | Beta |
| Poor visual function | ||||
| Blindness | 0.514/10.01 | 4.79–38.55 | ( | Beta |
| Visual impairment | 0.5327/10.38 | 5.32–39.95 | ( | Beta |
|
| ||||
| Ophthalmoscopy | 34.36 | 24.05–44.66 | ( | Gamma |
| Equipment | 3.16 | ( | ||
| Inputs | 0.87 | ( | ||
| Human resources (professional + training) | 30.32 (23.43+6.89 | ( | ||
| Wide-field imaging | 64.35 | 42.05–102.97 | −30%, +60% | Gamma |
| Equipment | 35.02 | Market value | ||
| Inputs | 1.13 | ( | ||
| Human resources (professional + training) | 28.15 (28.04+0.11 | ( | ||
| Combination | 58.20 | 40.74–93.12 | −30%, +60% | Gamma |
| Laser treatment | 642.09 | 449.46–834.72 | ( | Gamma |
| Equipment | 502.92 | ( | ||
| Inputs | 0.87 | ( | ||
| Human resources (professional + training) | 134.26 (72.22+62.04 | ( | ||
| Cataract surgery (facectomy) | 795.20 | 556.64–1,033.75 | ( | Gamma |
|
| ||||
| Good visual function in non-treated infants | 69.33 | 44.17–230.96 | ( | Gamma |
| Good visual function in treated infants | 190.63 | 106.53–675.13 | ( | Gamma |
| Poor visual function | 286.91 | 195.04–781.16 | ( | Gamma |
Parameters included clinical, epidemiological, utility and costs data and are presented as baseline and ranges values (high and low) with sources. Distribution of logarithmical probabilistic sensitivity (PSA) are presented for each parameter.
QALY, quality-adjusted life-years; ROP, retinopathy of pre-maturity; US $, US dollar.
Ophthalmoscopy training 33 h.
Wide-field imaging training 500 min.
100% wide-filed imaging and 25.8% ophthalmoscopy.
Treatment training 33 h.
Discount rate 5%.
Figure 2Tornado diagram of the 10 parameters that most impacted the incremental cost–utility ratio (ICUR). X axis represents the impact on the ICUR in US dollars (USD) cost per quality-adjusted life-years (QALY) of each parameter variation, and Y axis represents baseline parameters with an ICUR of USD 1,746,99/QALY. Orange and blue bands show each parameter high and low values, respectively.
Figure 3Monte Carlo probabilistic cost-effective acceptability curve. Interactions cost-effective percentages (y) between combination strategy (blue square) and ophthalmoscopy strategy (red triangle) by willingness-to-pay (WTP) (x) ranging from 0 to USD 2,000/QALY. Above USD 1,800/QALY combination strategy is 100% cost-effective.
Correlation between decimal visual acuity and quality-adjusted life-years (QALY) gained by infants with good and poor visual functions.
|
|
|
|
|---|---|---|
| 0 | 0 | |
| 0.00625 | 0.261 | |
| 0.0125 | 0.521 | 5 lines/1.2 QALY |
| 0.025 | 0.782 | |
| 0.05 | 1.043 | |
| 0.06 | 1.304 | |
| 0.08 | 1.564 | |
| 0.1 | 1.825 | 5 lines/1.2 QALY |
| 0.13 | 2.086 | |
| 0.16 | 2.346 | |
| 0.2 | 2.607 | |
| 0.25 | 2.868 | |
| 0.32 | 3.129 | 5 lines/1.2 QALY |
| 0.4 | 3.389 | |
| 0.5 | 3.65 |